Header Logo

Connection

SURENA MATIN to Kidney Neoplasms

Back to Details
This is a "connection" page, showing publications SURENA MATIN has written about Kidney Neoplasms.
SURENA MATIN
Connection Strength
14.501
Kidney Neoplasms
  1. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 09; 206(3):548-557.
    View in: PubMed
    Score: 0.299
  2. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 06; 37(6):354.e19-354.e26.
    View in: PubMed
    Score: 0.257
  3. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2019 03; 123(3):447-455.
    View in: PubMed
    Score: 0.249
  4. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034.
    View in: PubMed
    Score: 0.244
  5. Endoscopic Approaches to Upper Tract Urothelial Carcinoma. Urol Clin North Am. 2018 May; 45(2):267-286.
    View in: PubMed
    Score: 0.240
  6. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953.
    View in: PubMed
    Score: 0.230
  7. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
    View in: PubMed
    Score: 0.228
  8. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. Eur Urol. 2017 06; 71(6):987.
    View in: PubMed
    Score: 0.224
  9. Cryoablation for cT1b Renal Tumors? Yet To Be Determined. Eur Urol. 2017 01; 71(1):118-119.
    View in: PubMed
    Score: 0.217
  10. Kidney cancer: Quality-of-life outcomes in patients with small renal masses. Nat Rev Urol. 2016 08; 13(8):443-4.
    View in: PubMed
    Score: 0.214
  11. Predicting and Determining the Success of Percutaneous Ablation. J Urol. 2016 07; 196(1):7-8.
    View in: PubMed
    Score: 0.211
  12. Contemporary Evaluation and Management of Upper Tract Urothelial Cancer. Urology. 2016 Aug; 94:17-23.
    View in: PubMed
    Score: 0.208
  13. Positive Margins after Radical Nephrectomy with Venous Thrombectomy: Controversies and Treatment Options. J Urol. 2016 Feb; 195(2):241-2.
    View in: PubMed
    Score: 0.205
  14. Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. J Urol. 2015 Dec; 194(6):1567-74.
    View in: PubMed
    Score: 0.199
  15. Salvage surgery after energy ablation for renal masses. BJU Int. 2015 Jan; 115(1):74-80.
    View in: PubMed
    Score: 0.193
  16. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710.
    View in: PubMed
    Score: 0.175
  17. Accepting the positive results of unconventional methods. BJU Int. 2013 Jul; 112(1):5-6.
    View in: PubMed
    Score: 0.174
  18. Editorial comment. Urology. 2013 Aug; 82(2):268-9; discussion 269.
    View in: PubMed
    Score: 0.173
  19. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005.
    View in: PubMed
    Score: 0.170
  20. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7.
    View in: PubMed
    Score: 0.169
  21. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. J Urol. 2012 Mar; 187(3):822-6.
    View in: PubMed
    Score: 0.157
  22. Ablative therapies in renal cell carcinoma. Minerva Urol Nefrol. 2011 Sep; 63(3):237-50.
    View in: PubMed
    Score: 0.153
  23. Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J Endourol. 2011 Aug; 25(8):1323-7.
    View in: PubMed
    Score: 0.152
  24. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011 Jul; 78(1):61-7.
    View in: PubMed
    Score: 0.148
  25. Ablation of kidney tumors. Surg Oncol Clin N Am. 2011 Apr; 20(2):341-53, viii.
    View in: PubMed
    Score: 0.146
  26. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7.
    View in: PubMed
    Score: 0.143
  27. Laparoscopy-assisted radical nephrectomy with inferior vena caval thrombectomy for level II to III tumor thrombus: a single-institution experience and review of the literature. J Endourol. 2010 Jun; 24(6):1005-12.
    View in: PubMed
    Score: 0.140
  28. Determining failure after renal ablative therapy for renal cell carcinoma: false-negative and false-positive imaging findings. Urology. 2010 Jun; 75(6):1254-7.
    View in: PubMed
    Score: 0.138
  29. Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol. 2010 Jan; 183(1):333-8.
    View in: PubMed
    Score: 0.136
  30. A pilot trial of vascular targeted photodynamic therapy for renal tissue. J Urol. 2008 Jul; 180(1):338-42.
    View in: PubMed
    Score: 0.122
  31. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int. 2008 Sep; 102(8):940-5.
    View in: PubMed
    Score: 0.122
  32. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep. 2008 May; 10(3):253-8.
    View in: PubMed
    Score: 0.122
  33. Nephron-sparing probe ablative therapy: long-term outcomes. Curr Opin Urol. 2008 Mar; 18(2):150-6.
    View in: PubMed
    Score: 0.120
  34. Is radiofrequency ablation safe for solitary kidneys? Urology. 2007 May; 69(5):819-23; discussion 823.
    View in: PubMed
    Score: 0.113
  35. Laparoscopic radical nephroureterectomy for transitional cell carcinoma: where are we in 2007? Curr Opin Urol. 2007 Mar; 17(2):83-7.
    View in: PubMed
    Score: 0.112
  36. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006 Dec; 98(6):1176-80.
    View in: PubMed
    Score: 0.110
  37. Percutaneous radiofrequency ablation: minimally invasive therapy for renal tumors. Expert Rev Anticancer Ther. 2006 Dec; 6(12):1735-44.
    View in: PubMed
    Score: 0.110
  38. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006 Nov; 176(5):1973-7.
    View in: PubMed
    Score: 0.110
  39. Conventional and hand-assisted laparoscopic radical nephrectomy: Comparative analysis of 271 cases. J Endourol. 2006 Nov; 20(11):891-4.
    View in: PubMed
    Score: 0.110
  40. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology. 2006 Sep; 68(3):528-32.
    View in: PubMed
    Score: 0.109
  41. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology. 2006 Mar; 67(3):518-23.
    View in: PubMed
    Score: 0.105
  42. Recurrence and survival following laparoscopic radical nephroureterectomy with various forms of bladder cuff control. J Urol. 2005 Feb; 173(2):395-400.
    View in: PubMed
    Score: 0.097
  43. Bilateral metastatic renal synovial sarcoma. Urology. 2005 Feb; 65(2):389.
    View in: PubMed
    Score: 0.097
  44. Port-site metastasis: the influence of biology. Eur Urol. 2005 Mar; 47(3):357-60.
    View in: PubMed
    Score: 0.097
  45. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
    View in: PubMed
    Score: 0.092
  46. Laparoscopic radical nephroureterectomy: dilemma of the distal ureter. Curr Opin Urol. 2004 Mar; 14(2):61-5.
    View in: PubMed
    Score: 0.091
  47. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274. Eur Urol Oncol. 2024 Apr; 7(2):302-303.
    View in: PubMed
    Score: 0.089
  48. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology. 2023 12; 182:168-174.
    View in: PubMed
    Score: 0.088
  49. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors. Urol Oncol. 2024 01; 42(1):20.e17-20.e23.
    View in: PubMed
    Score: 0.087
  50. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2024 Apr; 7(2):266-274.
    View in: PubMed
    Score: 0.087
  51. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610. Eur Urol Oncol. 2023 12; 6(6):638-639.
    View in: PubMed
    Score: 0.086
  52. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. Eur Urol Focus. 2023 11; 9(6):1052-1058.
    View in: PubMed
    Score: 0.086
  53. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma. Urol Oncol. 2023 09; 41(9):387.e1-387.e7.
    View in: PubMed
    Score: 0.086
  54. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684.
    View in: PubMed
    Score: 0.086
  55. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6. Eur Urol. 2023 08; 84(2):e55-e56.
    View in: PubMed
    Score: 0.086
  56. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease. Eur Urol Focus. 2023 09; 9(5):807-812.
    View in: PubMed
    Score: 0.086
  57. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. J Urol. 2023 05; 209(5):872-881.
    View in: PubMed
    Score: 0.084
  58. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes. Urol Oncol. 2023 03; 41(3):147.e15-147.e21.
    View in: PubMed
    Score: 0.083
  59. Outcome of laparoscopic radical and open partial nephrectomy for the sporadic 4 cm. or less renal tumor with a normal contralateral kidney. J Urol. 2002 Oct; 168(4 Pt 1):1356-9; discussion 1359-60.
    View in: PubMed
    Score: 0.083
  60. Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Clin Genitourin Cancer. 2022 08; 20(4):e330-e338.
    View in: PubMed
    Score: 0.079
  61. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182.
    View in: PubMed
    Score: 0.078
  62. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
    View in: PubMed
    Score: 0.078
  63. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805. BJU Int. 2022 06; 129(6):718-722.
    View in: PubMed
    Score: 0.077
  64. Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy. J Urol. 2022 Feb; 207(2):284-292.
    View in: PubMed
    Score: 0.077
  65. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620.
    View in: PubMed
    Score: 0.076
  66. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23.
    View in: PubMed
    Score: 0.076
  67. The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. J Urol. 2021 Sep; 206(3):558-567.
    View in: PubMed
    Score: 0.075
  68. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. AJR Am J Roentgenol. 2021 07; 217(1):157-163.
    View in: PubMed
    Score: 0.075
  69. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 11; 128(5):568-574.
    View in: PubMed
    Score: 0.074
  70. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. Eur Urol Oncol. 2021 04; 4(2):170-179.
    View in: PubMed
    Score: 0.073
  71. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
    View in: PubMed
    Score: 0.072
  72. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
    View in: PubMed
    Score: 0.072
  73. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020 12; 126(6):745-753.
    View in: PubMed
    Score: 0.071
  74. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urol Oncol. 2020 09; 38(9):737.e11-737.e16.
    View in: PubMed
    Score: 0.071
  75. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. Eur Urol. 2020 08; 78(2):209-220.
    View in: PubMed
    Score: 0.070
  76. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urol Oncol. 2020 12; 38(12):933.e7-933.e12.
    View in: PubMed
    Score: 0.070
  77. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
    View in: PubMed
    Score: 0.070
  78. Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial. J Urol. 2020 Sep; 204(3):531-537.
    View in: PubMed
    Score: 0.069
  79. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2020 04; 203(4):690-698.
    View in: PubMed
    Score: 0.068
  80. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977.
    View in: PubMed
    Score: 0.066
  81. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
    View in: PubMed
    Score: 0.066
  82. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer. 2018 10 15; 124(20):4023-4031.
    View in: PubMed
    Score: 0.063
  83. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496.
    View in: PubMed
    Score: 0.062
  84. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020 01 15; 6(1):104-111.
    View in: PubMed
    Score: 0.062
  85. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World J Urol. 2018 Dec; 36(12):1973-1980.
    View in: PubMed
    Score: 0.062
  86. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757.
    View in: PubMed
    Score: 0.061
  87. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology. 2018 Jun; 116:114-119.
    View in: PubMed
    Score: 0.060
  88. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World J Urol. 2018 Jul; 36(7):1093-1101.
    View in: PubMed
    Score: 0.060
  89. The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology. 2018 May; 115:119-124.
    View in: PubMed
    Score: 0.060
  90. The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. Minerva Urol Nefrol. 2018 Apr; 70(2):109-125.
    View in: PubMed
    Score: 0.060
  91. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer. 2018 04; 16(2):e443-e450.
    View in: PubMed
    Score: 0.059
  92. Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. J Urol. 2018 02; 199(2):393-400.
    View in: PubMed
    Score: 0.058
  93. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res. 2017 10 01; 77(19):5313-5326.
    View in: PubMed
    Score: 0.058
  94. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627.
    View in: PubMed
    Score: 0.057
  95. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.056
  96. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 08; 198(2):281-288.
    View in: PubMed
    Score: 0.056
  97. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.056
  98. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.055
  99. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer. 2017 01 03; 116(1):77-84.
    View in: PubMed
    Score: 0.055
  100. Multiple Renal Artery Pseudoaneurysms in Patients Undergoing Renal Artery Embolization Following Partial Nephrectomy: Correlation with RENAL Nephrometry Scores. Cardiovasc Intervent Radiol. 2017 Feb; 40(2):202-209.
    View in: PubMed
    Score: 0.054
  101. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol. 2017 Mar; 35(3):355-365.
    View in: PubMed
    Score: 0.053
  102. Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psychooncology. 2017 09; 26(9):1361-1368.
    View in: PubMed
    Score: 0.053
  103. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol. 2017 Mar; 35(3):327-335.
    View in: PubMed
    Score: 0.053
  104. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
    View in: PubMed
    Score: 0.053
  105. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16.
    View in: PubMed
    Score: 0.052
  106. Re: Recurrence and survival following laparoscopic radical nephroureterectomy with various forms of bladder cuff control. J Urol. 2006 Jan; 175(1):391-2; author reply 392-3.
    View in: PubMed
    Score: 0.052
  107. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.052
  108. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82.
    View in: PubMed
    Score: 0.051
  109. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.051
  110. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15.
    View in: PubMed
    Score: 0.051
  111. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97.
    View in: PubMed
    Score: 0.051
  112. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.050
  113. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int. 2016 May; 117(5):775-82.
    View in: PubMed
    Score: 0.050
  114. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
    View in: PubMed
    Score: 0.050
  115. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.050
  116. Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. Eur Urol. 2016 Jan; 69(1):116-28.
    View in: PubMed
    Score: 0.049
  117. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015 Jul; 116(1):85-92.
    View in: PubMed
    Score: 0.049
  118. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22.
    View in: PubMed
    Score: 0.049
  119. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
    View in: PubMed
    Score: 0.049
  120. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol. 2015 Jun; 67(2):149-56.
    View in: PubMed
    Score: 0.049
  121. Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma. Carcinogenesis. 2015 Feb; 36(2):249-55.
    View in: PubMed
    Score: 0.048
  122. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol. 2015 Apr; 193(4):1101-7.
    View in: PubMed
    Score: 0.048
  123. Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome--clinicopathological features and comparative genomic analysis of 3 cases. Hum Pathol. 2014 Sep; 45(9):1966-72.
    View in: PubMed
    Score: 0.046
  124. Impact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol. 2015 Mar; 33(3):351-7.
    View in: PubMed
    Score: 0.046
  125. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9.
    View in: PubMed
    Score: 0.046
  126. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42.
    View in: PubMed
    Score: 0.045
  127. Randomized controlled trial of expressive writing for patients with renal cell carcinoma. J Clin Oncol. 2014 Mar 01; 32(7):663-70.
    View in: PubMed
    Score: 0.045
  128. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int. 2013 Nov; 112(7):917-24.
    View in: PubMed
    Score: 0.044
  129. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol. 2014 Feb; 32(1):265-71.
    View in: PubMed
    Score: 0.043
  130. Malignant epithelioid angiomyolipoma: tumor and metabolic response to everolimus as evaluated with positron emission tomography. Clin Genitourin Cancer. 2013 Dec; 11(4):e1-5.
    View in: PubMed
    Score: 0.043
  131. Real-time magnetic resonance imaging-guided cryoablation of small renal tumors at 1.5 T. Invest Radiol. 2013 Jun; 48(6):437-44.
    View in: PubMed
    Score: 0.043
  132. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol. 2013 Apr; 189(4):1214-21.
    View in: PubMed
    Score: 0.041
  133. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9.
    View in: PubMed
    Score: 0.041
  134. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2014 Jan; 65(1):210-7.
    View in: PubMed
    Score: 0.040
  135. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int. 2012 Dec; 110(11):1742-6.
    View in: PubMed
    Score: 0.040
  136. Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol. 2012 Apr 10; 9(5):266-73.
    View in: PubMed
    Score: 0.040
  137. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011 Dec; 22(12):2661-2666.
    View in: PubMed
    Score: 0.039
  138. Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J Urol. 2011 Nov; 186(5):2071-7.
    View in: PubMed
    Score: 0.038
  139. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol. 2011 Oct; 186(4):1236-41.
    View in: PubMed
    Score: 0.038
  140. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011 Dec; 60(6):1273-9.
    View in: PubMed
    Score: 0.038
  141. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol. 2011 May; 22(5):1243.
    View in: PubMed
    Score: 0.037
  142. Chyluria after radiofrequency ablation of renal tumors. J Vasc Interv Radiol. 2011 Jul; 22(7):924-7.
    View in: PubMed
    Score: 0.037
  143. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44.
    View in: PubMed
    Score: 0.036
  144. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011 May; 22(5):1048-1053.
    View in: PubMed
    Score: 0.036
  145. Identifying the risk of disease progression after surgery for localized renal cell carcinoma. BJU Int. 2010 Nov; 106(9):1277-83.
    View in: PubMed
    Score: 0.036
  146. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol. 2011 Jan; 42(1):146-50.
    View in: PubMed
    Score: 0.036
  147. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan; 59(1):10-5.
    View in: PubMed
    Score: 0.036
  148. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010 Nov; 184(5):1877-81.
    View in: PubMed
    Score: 0.036
  149. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010 Jul 15; 116(14):3378-88.
    View in: PubMed
    Score: 0.035
  150. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. Can J Urol. 2010 Jun; 17(3):5184-9.
    View in: PubMed
    Score: 0.035
  151. Impact of ischemia on renal function after laparoscopic partial nephrectomy: a multicenter study. J Urol. 2010 May; 183(5):1714-8.
    View in: PubMed
    Score: 0.035
  152. Characterization of contrast enhancement in the ablation zone immediately after radiofrequency ablation of renal tumors. J Vasc Interv Radiol. 2010 May; 21(5):690-5.
    View in: PubMed
    Score: 0.035
  153. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009 Nov 15; 125(10):2342-8.
    View in: PubMed
    Score: 0.034
  154. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct; 182(4):1271-9.
    View in: PubMed
    Score: 0.033
  155. Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU Int. 2010 Feb; 105(4):496-500.
    View in: PubMed
    Score: 0.033
  156. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81.
    View in: PubMed
    Score: 0.033
  157. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics. 2009 May-Jun; 29(3):741-54; discussion 755-7.
    View in: PubMed
    Score: 0.033
  158. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):801-7.
    View in: PubMed
    Score: 0.032
  159. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009 Feb; 73(2):337-41.
    View in: PubMed
    Score: 0.031
  160. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol. 2008 Sep; 18(5):474-80.
    View in: PubMed
    Score: 0.031
  161. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis. 2008 Nov; 29(11):2112-9.
    View in: PubMed
    Score: 0.031
  162. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul; 180(1):94-8.
    View in: PubMed
    Score: 0.030
  163. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer. 2008 Apr 01; 112(7):1480-8.
    View in: PubMed
    Score: 0.030
  164. Comparing lymphadenectomy during radical nephroureterectomy: open versus laparoscopic. Urology. 2008 Mar; 71(3):413-6.
    View in: PubMed
    Score: 0.030
  165. Contemporary strategies for treating nonhereditary synchronous bilateral renal tumors and the impact of minimally invasive, nephron-sparing techniques. Urol Oncol. 2008 Jan-Feb; 26(1):37-42.
    View in: PubMed
    Score: 0.029
  166. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 Nov; 178(5):1896-900.
    View in: PubMed
    Score: 0.029
  167. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol. 2007 Nov; 178(5):1878-82.
    View in: PubMed
    Score: 0.029
  168. Unexpected atypical findings on CT after radiofrequency ablation for small renal-cell carcinoma and the role of percutaneous biopsy. J Vasc Interv Radiol. 2007 Sep; 18(9):1186-91.
    View in: PubMed
    Score: 0.029
  169. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007 Oct; 178(4 Pt 1):1492-6.
    View in: PubMed
    Score: 0.029
  170. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007 Aug; 70(2):252-6.
    View in: PubMed
    Score: 0.029
  171. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer. 2007 Jun 15; 109(12):2439-44.
    View in: PubMed
    Score: 0.029
  172. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007 Mar; 177(3):855-60; discussion 860-1.
    View in: PubMed
    Score: 0.028
  173. Laparoscopic partial nephrectomy: experience in 60 cases. J Endourol. 2007 Jan; 21(1):71-4.
    View in: PubMed
    Score: 0.028
  174. Partial nephrectomy for renal urothelial tumors: clinical update. Urology. 2006 Mar; 67(3):490-5.
    View in: PubMed
    Score: 0.026
  175. Percutaneous transthoracic radiofrequency ablation of renal tumors using an iatrogenic pneumothorax. AJR Am J Roentgenol. 2005 Jul; 185(1):86-8.
    View in: PubMed
    Score: 0.025
  176. Evaluation of the intact specimen after laparoscopic radical nephrectomy for clinically localized renal cell carcinoma identifies a subset of patients at increased risk for recurrence. J Urol. 2005 May; 173(5):1487-90; discussion 1490-1.
    View in: PubMed
    Score: 0.025
  177. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol. 2005 May; 16(5):679-88.
    View in: PubMed
    Score: 0.025
  178. Radical laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: current status. BJU Int. 2005 Mar; 95 Suppl 2:68-74.
    View in: PubMed
    Score: 0.024
  179. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol. 2005 Jan; 173(1):38-41.
    View in: PubMed
    Score: 0.024
  180. Laparoscopic approaches to urologic malignancies. Curr Treat Options Oncol. 2003 Oct; 4(5):373-83.
    View in: PubMed
    Score: 0.022
  181. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol. 2003 Jul; 170(1):64-8.
    View in: PubMed
    Score: 0.022
  182. Modified Pfannenstiel incision for intact specimen extraction after retroperitoneoscopic renal surgery. Urology. 2003 Apr; 61(4):830-2.
    View in: PubMed
    Score: 0.021
  183. Laparoscopic radical nephrectomy for cancer with level I renal vein involvement. J Urol. 2003 Feb; 169(2):487-91.
    View in: PubMed
    Score: 0.021
  184. Laparoscopic partial nephrectomy with suture repair of the pelvicaliceal system. Urology. 2003 Jan; 61(1):99-104.
    View in: PubMed
    Score: 0.021
  185. Acute renal failure due to subcapsular renal hematoma in a solitary kidney: improvement after decompression. J Urol. 2002 Dec; 168(6):2526-7.
    View in: PubMed
    Score: 0.021
  186. Chronic kidney disease before and after partial nephrectomy. J Urol. 2011 Jan; 185(1):43-8.
    View in: PubMed
    Score: 0.009
  187. Outcomes of laparoscopic partial nephrectomy after fellowship training. JSLS. 2009 Apr-Jun; 13(2):154-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.